NEW YORK, NY / ACCESSWIRE / February 11, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Redwire Corporation f/k/a/ Genesis Park Acquisition Corp (NYSE:RDW)
CONTACT JAKUBOWITZ ABOUT RDW:
https://claimyourloss.com/securities/redwire-corporation-f-k-a-genesis-park-acquisition-corp-loss-submission-form/?id=23628&from=1
Class Period : August 11, 2021 - November 14, 2021
Lead Plaintiff Deadline : February 15, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) there were accounting issues at one of Redwire's subunits; (2) as a result, there were additional material weaknesses in Redwire's internal control over financial reporting; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Talkspace, Inc. f/k/a Hudson Executive Investment Corporation (NASDAQ:TALK)
CONTACT JAKUBOWITZ ABOUT TALK:
https://claimyourloss.com/securities/talkspace-inc-f-k-a-hudson-executive-investment-corporation-loss-submission-form/?id=23628&from=1
This lawsuit is on behalf of: (a) all persons or entities that purchased or otherwise acquired Talkspace securities between June 11, 2020 and November 15, 2021, both dates inclusive, and/or (b) all holders of Talkspace common stock as of the record date for the special meeting of shareholders held on June 17, 2021.
Lead Plaintiff Deadline : March 8, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Hudson Executive Investment Corporation ("HEIC") had overstated its competitive advantage and due diligence capabilities with respect to identifying and effectuating a merger with target companies; (ii) HEIC had conducted inadequate due diligence into then-private, pre-Merger Talkspace, or else ignored and/or failed to disclose multiple red flags concerning then-private, pre-Merger Talkspace's business and operations; (iii) Talkspace was experiencing significantly increased online advertising costs in its B2C business since the beginning of 2021; (iv) Talkspace was experiencing lower conversion rates in its online advertising in its business-to-consumer ("B2C") business; (v) as a result of (iii) and (iv) above, Talkspace was experiencing increased customer acquisition costs and more tepid B2C demand than represented to investors; (vi) as a result of (iii)-(v) above, Talkspace was suffering from ballooning customer acquisition costs and worsening growth and gross margin trends; (vii) Talkspace had overvalued its accounts receivables from certain of its health plan clients in its B2B business, which amounts required adjustment downward; and (viii) as a result of (iii)-(vii) above, Talkspace's 2021 financial guidance was not achievable and lacked any reasonable basis in fact.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
CONTACT JAKUBOWITZ ABOUT FENC:
https://claimyourloss.com/securities/fennec-pharmaceuticals-inc-loss-submission-form-2/?id=23628&from=1
Class Period : May 28, 2021 - November 26, 2021
Lead Plaintiff Deadline : April 11, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application ("NDA"); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE : Jakubowitz Law